Bausch + Lomb Corporation
BLCO.TO
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.84B
Close$
$-3.27
113.2% downside
Current Fair Value
113.2% downsideOvervalued by 113.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.84 Billion |
|---|---|
| Enterprise Value | $8.51 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.02 |
| Beta | 0.55 |
| Outstanding Shares | 357,100,000 |
Return
| Return on Equity | -2.62% |
|---|---|
| Return on Assets | -1.20% |
| Return on Invested Capital | 3.32% |
Valuation & Multiples
| P/E Ratio | -36.18 |
|---|---|
| PEG | 37.78 |
| Price to Sales | 1.77 |
| Price to Book Ratio | 1.37 |
| Enterprise Value to Revenue | 1.6 |
| Enterprise Value to EBIT | 21.44 |
| Enterprise Value to Net Income | -51 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$0.22
Average shareholder expectationRevenue Estimate
$1.94 B
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$0.31
Average shareholder expectationRevenue Estimate
$1.95 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bausch + Lomb Corp
13,000 employees
CEO: Brenton L. Saunders Bausch + Lomb Corporation is a global leader in eye health, delivering a wide range of products and services across the world. Its business is divided into three key areas: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, an...